论文部分内容阅读
目的 :对来本院接受放射治疗并复发的食管癌患者44例分组后进行单纯放疗和放化协同治疗并对其临床价值加以评价。方法 :选取自2006年5月15日~2010年5月15日来我院接受治疗的曾接受放疗且复发的食管癌患者44例,采用完全随机设计进行本次研究,按着随机化原则将本次研究的所有对象分为两组,即单纯放疗组和放化协同组。对二组的近期局控率、生存率以及死因构成比进行统计并分析。结果 :三年内放组因局部未得到有效控制死亡患者的死因构成比为55%(11/20)、因发生转移者死因构成比为25%(5/20)、因毒副作用发生其它器官损伤者的死因构成比为20%(4/20),放化组因局部未得到有效控制死亡患者的死因构成比为11.76%(2/17)、因发生转移者死因构成比为23.53%(4/17)、因毒副作用发生其它器官损伤者的死因构成比为64.71%(11/17),对其进行两两比较,二局部未控死因构成比,拒绝H0,二者异同较为直观,发生转移死因构成比,接受H0,尚不能认为二者有差异,毒副作用死因构成比,拒绝H0,二者差异显而易见。结论 :放疗同步化疗针对复发次再程食管癌患者是有效果的,对于近期局控率无大幅度改善,对于近三年的生存率也无大幅度改善,但从统计数据上发现其稍高于单纯放疗组,但其在死因构成比中以毒副作用为主,以后在临床用药过程中应加以重视。
OBJECTIVE: To study the clinical value of 44 patients with esophageal cancer who underwent radiotherapy and relapse to radiotherapy and radiotherapy, and to evaluate their clinical value. Methods: From May 15, 2006 to May 15, 2010 to treat 44 cases of esophageal cancer who had received radiation therapy and relapse, using a completely randomized design of the study, according to the principle of randomization All subjects in this study were divided into two groups, namely radiotherapy group and radiotherapy and chemotherapy group. The two groups of recent Bureau control rate, survival rate and cause of death constituent ratio statistics and analysis. Results: In the three years, the proportion of death causes in patients who died of local uncontrolled disease was 55% (11/20), the proportion of death causes was 25% (5/20) due to metastasis, and other organ damage (4/20). The proportion of death causes in patients receiving radiotherapy and chemotherapy was 11.76% (2/17), and the proportion of causes of death due to metastasis was 23.53% (4) / 17), the proportion of death causes of other organ damage due to toxic side effects was 64.71% (11/17), comparing them pairwise and two, the proportion of uncontrollable death causes of two localities was declined, H0 was rejected, and the similarities and differences between the two were more obvious The proportion of death causes transferred to accept H0, still can not think there are differences between the toxic and side effects constitute the ratio of deaths, rejected H0, the difference between the two is obvious. Conclusion: Radiotherapy concurrent chemotherapy for patients with recurrent esophageal re-esophageal cancer is effective, for the recent local control rate no significant improvement in the survival rate for the past three years also did not significantly improve, but from the statistical data found slightly higher In the simple radiotherapy group, but its proportion in the cause of death to toxic and side effects mainly in the future course of clinical medication should be taken seriously.